These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30787232)

  • 1. EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma.
    Nozawa T; Okada M; Natsumeda M; Eda T; Abe H; Tsukamoto Y; Okamoto K; Oishi M; Takahashi H; Fujii Y; Kakita A
    Neurol Med Chir (Tokyo); 2019 Mar; 59(3):89-97. PubMed ID: 30787232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived growth factor receptor α/glial fibrillary acidic protein expressing peritumoral astrocytes associate with shorter median overall survival in glioblastoma patients.
    Leiss L; Mega A; Olsson Bontell T; Nistér M; Smits A; Corvigno S; Rahman MA; Enger PØ; Miletic H; Östman A
    Glia; 2020 May; 68(5):979-988. PubMed ID: 31769546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
    Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
    J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 8. EGFRvIII expression triggers a metabolic dependency and therapeutic vulnerability sensitive to autophagy inhibition.
    Jutten B; Keulers TG; Peeters HJM; Schaaf MBE; Savelkouls KGM; Compter I; Clarijs R; Schijns OEMG; Ackermans L; Teernstra OPM; Zonneveld MI; Colaris RME; Dubois L; Vooijs MA; Bussink J; Sotelo J; Theys J; Lammering G; Rouschop KMA
    Autophagy; 2018; 14(2):283-295. PubMed ID: 29377763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of glioblastoma multiforme stem-like cells leads to downregulation of EGFR and EGFRvIII and decreased tumorigenic and stem-like cell potential.
    Stockhausen MT; Kristoffersen K; Stobbe L; Poulsen HS
    Cancer Biol Ther; 2014 Feb; 15(2):216-24. PubMed ID: 24525857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.
    Choi D; Montermini L; Kim DK; Meehan B; Roth FP; Rak J
    Mol Cell Proteomics; 2018 Oct; 17(10):1948-1964. PubMed ID: 30006486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clustered localization of EGFRvIII in glioblastoma cells as detected by high precision localization microscopy.
    Boyd PS; Struve N; Bach M; Eberle JP; Gote M; Schock F; Cremer C; Kriegs M; Hausmann M
    Nanoscale; 2016 Dec; 8(48):20037-20047. PubMed ID: 27883139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
    Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
    Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
    Saikali S; Avril T; Collet B; Hamlat A; Bansard JY; Drenou B; Guegan Y; Quillien V
    J Neurooncol; 2007 Jan; 81(2):139-48. PubMed ID: 17004103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A; Lawler SE; Nowicki MO; Ray Chaudhury A; Van Brocklyn JR
    J Neurooncol; 2011 May; 102(3):353-66. PubMed ID: 20938717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
    van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
    Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of EGFRvIII in glioblastoma: prognostic significance revisited.
    Montano N; Cenci T; Martini M; D'Alessandris QG; Pelacchi F; Ricci-Vitiani L; Maira G; De Maria R; Larocca LM; Pallini R
    Neoplasia; 2011 Dec; 13(12):1113-21. PubMed ID: 22241957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.
    Emlet DR; Gupta P; Holgado-Madruga M; Del Vecchio CA; Mitra SS; Han SY; Li G; Jensen KC; Vogel H; Xu LW; Skirboll SS; Wong AJ
    Cancer Res; 2014 Feb; 74(4):1238-49. PubMed ID: 24366881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.